Is Semaglutide Going Away? The Brand vs Compounded Distinction in 2026

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 13 sources cited

Key Takeaways

• Semaglutide as a molecule is firmly established and widely available. Brand Ozempic, Wegovy, and Rybelsus are all in full production
• The February 21, 2025 FDA shortage resolution did affect compounded semaglutide availability, but brand product was not affected by that decision
• Novo Nordisk's 2024 acquisition of Catalent manufacturing capacity expanded global semaglutide production substantially
• Wegovy received a cardiovascular risk-reduction indication in March 2024, broadening the use case and entrenching the drug clinically
• STEP 1 trial data documents a 14.9% mean weight loss at week 68 for semaglutide; this efficacy profile applies to brand Wegovy at the 2.4 mg weekly dose

Direct answer

No, semaglutide is not going away. Brand Ozempic, Wegovy, and Rybelsus are widely available, with Novo Nordisk's manufacturing capacity expanded through the 2024 Catalent acquisition. The "going away" question typically arises from confusion with the FDA's February 21, 2025 decision to remove semaglutide from the drug shortage list, which narrowed compounded semaglutide availability but did not affect brand supply.

Table of contents

1. The brand-vs-compounded distinction (read this first)
2. The Novo Nordisk capacity arc
3. Semaglutide's expanding FDA approvals
4. What changed with compounded semaglutide
5. The Wegovy cardiovascular indication and what it means long-term
6. Pricing and access in 2026
7. Patents and the eventual generic question
8. The investigational landscape
9. Decision framework
10. FAQ
11. Sources

The brand-vs-compounded distinction (read this first)

Two different products share the name "semaglutide":

• Brand semaglutide - Ozempic, Wegovy, Rybelsus - manufactured by Novo Nordisk under cGMP standards, FDA-approved with full clinical trial backing
• Compounded semaglutide - prepared by 503A pharmacies for individual patients under USP 797 standards, not FDA-approved, available through different regulatory and supply pathways

Each has its own availability story. When someone asks "is semaglutide going away," the answer depends on which category they mean. This article focuses on the brand category and the molecule itself. For the compounded picture specifically, see the article on compounded semaglutide availability.

The Novo Nordisk capacity arc

Semaglutide demand began outpacing supply in March 2022. Ozempic prescriptions for type 2 diabetes and Wegovy for obesity (launched June 2021) overwhelmed initial production capacity. The FDA placed semaglutide on its drug shortage list and the shortage persisted for nearly three years.

The supply response was substantial. Novo Nordisk invested in manufacturing expansion at its Bagsvaerd, Denmark headquarters and the Clayton, North Carolina facility. The decisive move came in late 2024, when Novo Holdings (Novo Nordisk's parent) completed a $16.5 billion acquisition of Catalent's biologics business. The transaction transferred three Catalent sites (Bloomington, Indiana; Brussels, Belgium; Anagni, Italy) to Novo Nordisk for semaglutide and adjacent GLP-1 production.

The capacity math changed quickly. Fill-finish capacity expanded by approximately 40% of Novo Nordisk's pre-acquisition global production. By Q1 2025, supply consistently met demand. The FDA reviewed the data and resolved the semaglutide shortage on February 21, 2025.

Semaglutide's expanding FDA approvals

Semaglutide's regulatory portfolio has grown substantially since the original approval:

Date	Action	Indication
December 2017	Original approval	Ozempic for type 2 diabetes (subcutaneous)
September 2019	Approval	Rybelsus for type 2 diabetes (oral)
June 2021	Approval	Wegovy for chronic weight management in adults with obesity or overweight with comorbidities
December 2022	Pediatric approval	Wegovy for adolescents (age 12+) with obesity
March 2024	Indication expansion	Wegovy for cardiovascular event reduction in adults with established CV disease and overweight or obesity
2025-2026 (under review)	Various	Possible additional indications for chronic kidney disease, MASH, heart failure with preserved ejection fraction

An expanding indication set typically signals long-term commercial commitment and entrenches the drug in clinical guidelines. Each indication broadens the addressable patient population.

What changed with compounded semaglutide

The February 21, 2025 shortage resolution did affect compounded availability, and the framing of "semaglutide going away" largely reflects that change.

During the shortage period, 503A and 503B compounders could prepare semaglutide under expanded authority. After the resolution:

• 503B outsourcing facilities could no longer compound semaglutide for office stock
• 503A pharmacies could continue compounding only for individual patients with documented clinical justification
• Telehealth platforms that had been using shortage status as the standalone basis for compounded prescriptions had to adapt

The 503A patient-specific pathway continues. Patients with documented individualized clinical reasons (allergen sensitivity, dose individualization, concentration adjustment, preservative-free formulation needs) can still access compounded semaglutide through licensed pharmacies. The pathway is narrower than during the shortage period but is preserved by federal statute.

The Wegovy cardiovascular indication and what it means long-term

The March 2024 FDA approval of Wegovy for cardiovascular event reduction (based on the SELECT trial) was a major moment for semaglutide's long-term position. The approval was the first time a weight-management medication received an indication for reducing cardiovascular events.

The SELECT trial enrolled 17,604 patients with established cardiovascular disease and overweight or obesity, without diabetes. Patients received semaglutide 2.4 mg weekly or placebo for a mean of approximately 40 months. The trial reported a 20% reduction in major adverse cardiovascular events (MACE) in the semaglutide arm compared to placebo.

The clinical and regulatory implications are substantial. Cardiovascular indications typically secure broader insurance coverage and longer commercial lifespans for pharmaceuticals. The Wegovy CV indication essentially guarantees that semaglutide remains in widespread use through the end of its patent life and likely beyond, as cardiovascular protection becomes a primary use case alongside weight management.

Pricing and access in 2026

Brand semaglutide pricing has evolved in parallel with the shortage resolution.

List prices for Ozempic and Wegovy remain in the $1,300/month range at retail, with manufacturer rebates negotiated separately with payers. Most commercially-insured patients pay much less, typically $25 to a few hundred dollars depending on their plan's coverage tier.

The substantive change in 2025 was the launch of expanded NovoCare Wegovy Self-Pay at $499/month for patients without insurance coverage or whose coverage excludes obesity medications. This is broadly accessible and represents a meaningful new entry point for self-pay patients.

Compounded semaglutide through 503A pharmacies typically runs $200-$400/month for patients with documented clinical justification. The cost gap between compounded and self-pay brand has narrowed significantly compared to the 2022-2023 environment when compounded prices ran far below $1,300 retail.

Patents and the eventual generic question

Novo Nordisk holds multiple patents covering semaglutide. The primary composition-of-matter patent extends through approximately 2031-2033, with method-of-use patents and manufacturing patents potentially extending further. Generic semaglutide is not expected in the U.S. market before the early 2030s, and timing depends on patent challenges, regulatory exclusivity periods, and biosimilar approval pathways.

Beyond patent expiry, semaglutide is a peptide rather than a small molecule, which complicates the generic landscape. Biosimilar versions, when approved, may not be as drop-in substitutable as traditional small-molecule generics. The economics of biosimilar competition typically yield smaller price reductions than small-molecule generic competition.

For the "is semaglutide going away" question, the patent picture supports continued widespread brand use through at least the early 2030s. Generic or biosimilar competition will eventually arrive, but it will represent expanded options, not discontinuation.

The investigational landscape

Several investigational drugs in advanced trials could affect semaglutide's market position.

Cagrisema (Novo Nordisk) combines cagrilintide (an amylin analog) with semaglutide. Phase 3 trials reported meaningful weight loss potentially exceeding semaglutide monotherapy. If approved, cagrisema would be a sister product to Wegovy rather than a replacement. This medication is investigational and not FDA-approved. FormBlends does not sell or supply cagrisema.

Retatrutide (Eli Lilly) is a triple agonist (GLP-1, GIP, glucagon) in Phase 3 trials. Phase 2 data showed potential weight loss exceeding tirzepatide. This medication is investigational and not FDA-approved. FormBlends does not sell or supply retatrutide.

Orforglipron (Eli Lilly) is an oral small-molecule GLP-1 agonist. If approved, it would expand oral options beyond Rybelsus. This medication is investigational and not FDA-approved. FormBlends does not sell or supply orforglipron.

None of these displaces semaglutide. They are additions to the category that may serve specific patient profiles or fill specific positioning gaps.

Decision framework

If you read "semaglutide is going away" and worried: The brand drug is not going away. The compounded pathway narrowed but remains available with documented clinical justification.

If you are starting semaglutide therapy: Brand Wegovy or Ozempic is the default. The $499 NovoCare self-pay tier is broadly accessible. Compounded is appropriate when individualized clinical reasons exist.

If you have been on compounded semaglutide: Evaluate whether your prescriber documents clinical justification for continued compounded use, or whether transition to brand at $499 self-pay makes sense.

If you are on Ozempic for type 2 diabetes: Coverage continuity is the main concern. Most commercial plans, Medicare, and many Medicaid programs cover Ozempic for diabetes. Supply is not the bottleneck in 2026.

FAQ

Is semaglutide going away?
No. Brand product is widely available; compounded narrowed but did not close.

Are Ozempic and Wegovy still being made?
Yes, with expanded production after the Catalent acquisition.

Did Novo Nordisk stop making Ozempic?
No.

Why are people asking if semaglutide is going away?
Confusion with the February 2025 shortage resolution and its effect on compounded availability.

Is there still a semaglutide shortage?
No. Resolved February 21, 2025.

Will Wegovy be discontinued?
No. Expanding indications including the 2024 cardiovascular approval.

Can I still get semaglutide in 2026?
Yes, through prescription.

Is the patent expiring?
Not until the early 2030s.

What new drugs might replace semaglutide?
Investigational drugs are additions, not replacements.

Is Wegovy self-pay available?
Yes, $499/month through NovoCare.

Sources

1. FDA Drug Shortage List update, February 21, 2025, resolving semaglutide shortage
2. Wilding JPH et al., "Once-Weekly Semaglutide in Adults with Overweight or Obesity," NEJM, March 2021 (STEP 1)
3. Lincoff AM et al., "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes," NEJM, November 2023 (SELECT)
4. Novo Holdings press release, Catalent acquisition completion, December 2024
5. Ozempic FDA prescribing information, December 2017 with updates
6. Wegovy FDA prescribing information, June 2021 with updates
7. Wegovy cardiovascular indication approval, FDA, March 2024
8. Rybelsus FDA prescribing information, September 2019
9. NovoCare Wegovy Self-Pay program announcement and expansion
10. Federal Food, Drug, and Cosmetic Act Sections 503A and 503B
11. U.S. Patent and Trademark Office records on semaglutide patents
12. Cagrisema, retatrutide, orforglipron Phase 3 trial registrations (clinicaltrials.gov)
13. Endocrine Society Clinical Practice Guideline on Obesity, 2023

Footer disclaimers

Platform Disclaimer. FormBlends is a telehealth platform connecting patients with licensed prescribers for evaluation and prescription of GLP-1 therapy. We do not manufacture or dispense medications directly; clinical and pharmacy decisions rest with licensed professionals.

Compounded Medication Notice. Compounded semaglutide is prepared by licensed 503A pharmacy partners for individual patients with documented clinical justification. It is not FDA-approved. Brand Ozempic and Wegovy have specific clinical trial backing (STEP and SELECT programs) that does not transfer to compounded preparations.

Results Disclaimer. Outcomes vary. STEP 1 reported a 14.9% mean weight loss at week 68 for semaglutide 2.4 mg. Your result will depend on adherence, dose, baseline weight, and individual response. Adverse events including gastrointestinal effects, gallbladder events, and pancreatitis are possible.

Trademark Notice. Ozempic, Wegovy, Rybelsus, and NovoCare are trademarks or service marks of Novo Nordisk A/S. FormBlends is independent and not affiliated with Novo Nordisk.